LMAT Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
70.4M
+5.8%
66.6M
+3.3%
64.5M
+5.6%
61.0M
-5.0%
64.2M
Cost of Revenue
19.6M
+8.1%
18.2M
-0.6%
18.3M
+21.0%
15.1M
-21.6%
19.3M
Gross Profit
50.8M
+4.9%
48.4M
+4.8%
46.2M
+0.5%
46.0M
+2.2%
45.0M
Operating Expenses
30.4M
-0.8%
30.6M
+11.9%
27.4M
+6.7%
25.6M
-11.1%
28.8M
R&D
4.8M
+19.4%
4.1M
+14.9%
3.5M
+19.0%
3.0M
-16.1%
3.5M
SG&A
25.5M
-3.9%
26.6M
+11.5%
23.8M
+5.1%
22.7M
-10.4%
25.3M
Operating Income
20.4M
+14.8%
17.8M
-5.6%
18.8M
-7.3%
20.3M
+25.8%
16.1M
EBITDA
23.1M
+13.1%
20.4M
-4.8%
21.4M
-6.5%
22.9M
+22.0%
18.8M
Net Income
17.1M
+8.7%
15.7M
+0.6%
15.6M
-10.3%
17.4M
+26.0%
13.8M
EPS (Basic)
$0.75
+8.7%
$0.69
+0.0%
$0.69
-10.4%
$0.77
+26.2%
$0.61
EPS (Diluted)
$0.74
+8.8%
$0.68
-5.6%
$0.72
-4.0%
$0.75
+25.0%
$0.60
Shares (Diluted)
24.5M
+6.5%
23.0M
+7.0%
21.5M
-11.7%
24.4M
+6.6%
22.9M
LeMaitre Vascular (LMAT) โ€” Financials